Article
Mutation of PA4292 in Pseudomonas aeruginosa Increases β-Lactam Resistance through Upregulating Pyocyanin Production.
Antimicrobial agents and chemotherapy - 19 Jul 2022
Zhao Xinrui, Jin Yongxin, Bai Fang, Cheng Zhihui, Wu Weihui, Pan Xiaolei
Abstract excerpt
Metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa is increasingly reported worldwide and usually causes infections with high mortality rates. Aztreonam/avibactam is a β-lactam/β-lactamase inhibitor (BLBLI) combination that is under clinical trials. The advantage of aztreonam/avibactam over the currently used BLBLIs lies in its effectiveness against MBL-producing pathogens, making it one of the few drugs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
